Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools (NASDAQ: LAB) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools (NASDAQ: LAB) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Investors can expect a post-close release and likely an associated investor webcast or call timing to be announced separately by the company.
Details
News Market Reaction – LAB
On Feb 10, the day this news came out, LAB closed 1.59% below the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Earnings release date
- February 24, 2026
- Scheduled Q4 and full-year 2025 results release after U.S. market close
Historical Context
-
Completed SomaLogic sale to Illumina with substantial cash proceeds and royalties.
-
Preliminary Q4 and FY2025 revenue and cash outlook for continuing operations.
-
Collaboration to integrate HCR imaging with Hyperion Imaging System for IMC.
-
Illumina update including definitive agreement to acquire SomaLogic from LAB.
-
Q3 2025 results with revenue decline but cost savings and EBITDA targets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2026 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.